Proteo Biotech AG (PTEO.OB) And Proteo Inc. (PTEO.OB) Anti-Inflammatory Agent "Elafin" Has Been Successfully Tested In A Phase I Clinical Trial
12/13/2005 11:50:24 AM
KIEL, Germany--(BUSINESS WIRE)--Dec. 13, 2005--The first phase in the clinical trial of the newly developed drug Elafin has been successfully completed as announced by Proteo Biotech AG, a wholly owned subsidiary of Proteo Inc. (OTCBB:PTEO). Elafin, a recombinant human protein, is intended for the treatment of inflammatory diseases and is administered intravenously. The trial aimed to assess the safety and tolerability of this biotechnologically manufactured drug.
comments powered by